Sculptor Capital’s Forte Biosciences FBRX Stock Holding History

Sculptor Capital’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-556	Closed	-$30K	–	1249
2021 Q4	$30K	Hold	556	–	–	﹤0.01%	1100
2021 Q3	$41K	Buy	+556	New	+$308K	﹤0.01%	929

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sculptor Capital's FBRX Position: Q1 2022 in Review

Sculptor Capital sold out of Forte Biosciences (FBRX) in Q1 2022, closing a stake of 556 shares — an estimated $30K sold.

Sculptor Capital first reported a position in FBRX in Q3 2021 and held it in 2 quarters. The position peaked at $41K in Q3 2021. 52 funds tracked by Wall St. Rank hold FBRX as of Q1 2022.

Sculptor Capital reported no remaining Forte Biosciences position as of Q1 2022 after selling out during the quarter.
Sculptor Capital sold 556 Forte Biosciences shares in Q1 2022, an estimated $30K.
Sculptor Capital first reported a position in Forte Biosciences in Q3 2021 and held it in 2 quarters.
Sculptor Capital's Forte Biosciences position peaked at $41K in Q3 2021.
52 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2022.

Based on Sculptor Capital's 13F filing for Q1 2022, filed 13 May 2022.